Physician profile
Eugene Eisenberg
NPI 1255358750
$2,983.46
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $829 · 2020: $678 · 2021: $899 · 2022: $577.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $633.42 | 2020-2022 | |
| Alexion Pharmaceuticals, INC. | $581.80 | 2019-2022 | |
| Novo Nordisk INC | $448.06 | 2019-2022 | |
| Radius Health, INC. | $264.66 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $224.60 | 2019-2022 | |
| Amgen INC. | $165.45 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.01 | 2019-2022 | |
| Ultragenyx Pharmaceutical INC. | $124.72 | 2020-2021 | |
| Boston Scientific Corporation | $115.12 | 2019-2021 | |
| Lilly USA, LLC | $60.48 | 2019-2021 | |
| Medtronic, INC. | $49.39 | 2021 | |
| Zealand Pharma US, INC. | $46.36 | 2021-2022 | |
| Companion Medical, INC. | $34.50 | 2019 | |
| Corcept Therapeutics | $33.18 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.49 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $22.22 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Eisenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.